The patient has received prior therapy with bevacizumab, ramucirumab or any PARP inhibitor, including olaparib
Any previous treatment with a PARP inhibitor, including olaparib and/or known hypersensitivity to any of the excipients of study treatment
Any previous treatment with a PARP inhibitor, including olaparib
Patients who have received any previous treatment with a PARP inhibitor, including olaparib
Prior treatment with a PARP inhibitor, including olaparib.
Any previous treatment with PARP inhibitor, including olaparib
Any previous treatment with a PARP inhibitor, including Olaparib
Prior therapy with any PARP inhibitor, including olaparib
Any previous treatment with PARP inhibitor, including olaparib.
Any previous treatment with PARP inhibitor, including olaparib.
Prior therapy with a PARP inhibitor (e.g., olaparib, talazoparib, veliparib, niraparib, rucaparib)
Patients are not eligible who have received prior PARP inhibitors (including but not limited to veliparib, talazoparib, rucaparib, and olaparib)
Any previous treatment with PARP inhibitor, including olaparib
Any previous treatment with a PARP inhibitor, including olaparib
Prior treatment with veliparib (ABT-) or other PARP inhibitors (e.g., olaparib)
Patients must not have had prior exposure to any agent with a PARP inhibitor (e.g., veliparib, olaparib, rucaparib, niraparib, talazoparib [BMN ]) as its primary pharmacology
Patients must not have received prior PARP inhibitor therapy including, but not limited to ABT-, olaparib, rucaparib, and talazoparib (BMN)
Any previous treatment with a Polyadenosine 'diphosphoribose polymerisation (PARP) inhibitor, including olaparib.
Any previous treatment with a PARP inhibitor, including olaparib.
Any previous treatment with PARP inhibitor, including olaparib, for the treatment of small cell lung cancer.
Any previous treatment with a PARP inhibitor, including olaparib;
